The SEC62 gene is amplified in a number of cancers, including lung adenocarcinomas, prostate, thyroid and head and neck squamous cell carcinoma; accordingly it has been hypothesized that excess SEC62 may not be incorporated into SEC61 complexes and instead lead to sensitized ER‐phagy responses and, consequently, resistance to anticancer ER stress 114. Here, SEC62 is linked to head and neck squamous cell carcinoma.